Cell Signaling Technology
|Privately held company|
|Industry||Life Science, Manufacturing|
|Michael Comb, President and CEO
Roberto Polakiewicz, CSO
Fenel Eloi, CFO, COO
|Products||Antibodies, ELISA Kits, ChIP Kits, Proteomics kits|
Number of employees
|450 — 500|
|Subsidiaries||Cell Signaling Technology Japan, K.K.
Cell Signaling Technology (China) Limited
Cell Signaling Technology Europe, B.V.
Cell Signaling Technology, Inc. (CST) is a privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related regents used to study the cell signaling pathways that impact human health. CST maintains an in-house research program, particularly in the area of cancer research, and has published scientific papers in many peer-reviewed journals.
Originally housed in the Cummings Center (Beverly, Massachusetts), CST moved to its current United States headquarters located at the former King’s Grant Inn (Danvers, Massachusetts) in late 2005. Following extensive renovation, the U.S. Green Building Council has certified the current headquarters as a LEED (Leadership in Energy and Environmental Design) certified facility in 2007. In 2008 and 2009, CST expanded its overseas operations, establishing subsidiary offices in the People’s Republic of China, Japan, and the Netherlands.
Cell Signaling Technology, Inc. (CST) was named as one of the “Top 100 Places to Work” in a 2009-2013 survey published by the Boston Globe.
In addition to product development and production, CST is also involved in the development of new technologies for signaling analysis as well as mechanistic cell biology research, particularly in the field of cancer research. CST scientists publish their findings in peer-reviewed journals, including Nature Cell Biology, Cell, Molecular and Cellular Biology, and Journal of Biological Chemistry.
CST curates and maintains §PhosphoSitePlus, a web-based bioinformatics resource that details post-translational modifications (PTMs) in human, mouse and rat proteins. The types of PTMs curated include phosphorylation, acetylation, methylation, ubiquitylation, glycosylation, etc. This freely accessible, online resource is funded in part through grant support from the NIH, and most recently through the NIH BD2K initiative.
- A lab with a view: New research space reflects company's open, research-driven philosophy
- King's Grant Inn goes from hotel to biotech HQ
- NEW Room At The Inn
- Public buildings take the 'LEED' in New England
- Cell Signaling Technology opens unit in Japan
- Cell Signaling Technology buys Dutch distributor
- Globe Top 100 Places to Work
- Wimberly, H.; Brown, J. R.; Schalper, K.; Haack, H.; Silver, M. R.; Nixon, C.; Bossuyt, V.; Pusztai, L.; Lannin, D. R.; Rimm, D. L. (2015). "PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer". Cancer Immunology Research. 3 (4): 326–32. PMC . PMID 25527356. doi:10.1158/2326-6066.CIR-14-0133.
- Fan, Jun; Kang, Hee-Bum; Shan, Changliang; Elf, Shannon; Lin, Ruiting; Xie, Jianxin; Gu, Ting-Lei; Aguiar, Mike; Lonning, Scott; Chung, Tae-Wook; Arellano, Martha; Khoury, Hanna J.; Shin, Dong M.; Khuri, Fadlo R.; Boggon, Titus J.; Kang, Sumin; Chen, Jing (2014). "Tyr-301 Phosphorylation Inhibits Pyruvate Dehydrogenase by Blocking Substrate Binding and Promotes the Warburg Effect". Journal of Biological Chemistry. 289 (38): 26533–41. PMC . PMID 25104357. doi:10.1074/jbc.M114.593970.
- Li, Na; Fassl, Anne; Chick, Joel; Inuzuka, Hiroyuki; Li, Xiaoyu; Mansour, Marc R.; Liu, Lijun; Wang, Haizhen; King, Bryan; Shaik, Shavali; Gutierrez, Alejandro; Ordureau, Alban; Otto, Tobias; Kreslavsky, Taras; Baitsch, Lukas; Bury, Leah; Meyer, Clifford A.; Ke, Nan; Mulry, Kristin A.; Kluk, Michael J.; Roy, Moni; Kim, Sunkyu; Zhang, Xiaowu; Geng, Yan; Zagozdzon, Agnieszka; Jenkinson, Sarah; Gale, Rosemary E.; Linch, David C.; Zhao, Jean J.; Mullighan, Charles G.; Harper, J. Wade; Aster, Jon C.; Aifantis, Iannis; von Boehmer, Harald; Gygi, Steven P.; Wei, Wenyi; Look, A. Thomas; Sicinski, Piotr (2014). "Cyclin C is a haploinsufficient tumour suppressor". Nature Cell Biology. 16 (11): 1080–91. PMC . PMID 25344755. doi:10.1038/ncb3046.
- Lawan, Ahmed; Zhang, Lei; Gatzke, Florian; Min, Kisuk; Jurczak, Michael J.; Al-Mutairi, Mashael; Richter, Patric; Camporez, Joao Paulo G.; Couvillon, Anthony; Pesta, Dominik; Roth Flach, Rachel J.; Shulman, Gerald I.; Bennett, Anton M. (2015). "Hepatic Mitogen-Activated Protein Kinase Phosphatase 1 Selectively Regulates Glucose Metabolism and Energy Homeostasis". Molecular and Cellular Biology. 35 (1): 26–40. PMC . PMID 25312648. doi:10.1128/MCB.00503-14.
- Israelsen, William J.; Dayton, Talya L.; Davidson, Shawn M.; Fiske, Brian P.; Hosios, Aaron M.; Bellinger, Gary; Li, Jie; Yu, Yimin; Sasaki, Mika; Horner, James W.; Burga, Laura N.; Xie, Jianxin; Jurczak, Michael J.; DePinho, Ronald A.; Clish, Clary B.; Jacks, Tyler; Kibbey, Richard G.; Wulf, Gerburg M.; Di Vizio, Dolores; Mills, Gordon B.; Cantley, Lewis C.; Vander Heiden, Matthew G. (2013). "PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells". Cell. 155 (2): 397–409. PMC . PMID 24120138. doi:10.1016/j.cell.2013.09.025.
- Hornbeck, Peter V.; Zhang, Bin; Murray, Beth; Kornhauser, Jon M.; Latham, Vaughan; Skrzypek, Elzbieta (2015). "PhosphoSitePlus, 2014: mutations, PTMs and recalibrations". Nucleic Acids Res. 43 (1): D512–20. PMC . PMID 25514926. doi:10.1093/nar/gku1267.
- "Cell Signaling Technology Announces the Availability of PhosphoScan® Profiling Technology and PhosphoSite® Knowledgebase to Academic Researchers" (Press release). Cell Signaling Technology. October 31, 2007. Retrieved October 24, 2015.